 |
IDEA Collider: Innovation & Asymmetric Learning in PharmaAuthor: IDEA Pharma, SAI MedPartners
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma & Head of Strategy and Thought Leadership at SAI MedPartners, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace othersand what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * Whats broken in traditional innovation modelsand how do we fix it? Listen and subscribe on all major platforms. Language: en Genres: Business, Life Sciences, Marketing, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds
Episode 12
Monday, 27 April, 2026
In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation. The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment. They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology. Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth. This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode Timestamps 00:00 – Introduction and Vir’s transformation story 00:40 – Marianne De Backer’s 30+ year pharma journey 02:42 – Vir’s origins and post-COVID strategic pivot 04:42 – Taking over as CEO during a crisis 06:33 – Lessons from the biotech downturn (“biotech winter”) 08:56 – Astellas partnership and T-cell engager strategy 09:52 – ProXtend platform: masked T-cell engagers explained 13:24 – Clinical data, safety, and tumor targeting 15:32 – Integrating new teams and scientific expertise 17:38 – Expanding the pipeline (HER2, EGFR, oncology) 19:50 – Hepatitis delta program and commercialization plans 22:11 – Funding strategy and biotech market outlook 25:37 – FDA interactions and regulatory perspective 28:13 – AI in drug discovery and clinical trials (Daisy platform) 31:34 – Culture: grit, ingenuity, collaboration, authenticity 34:21 – Personal reflections and leadership mindset 35:46 – Closing thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Marianne De Backer; LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/ Website: https://www.vir.bio/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ LinkedIn: https://www.linkedin.com/company/idea-pharma Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/
